Review of the ATHOS 3 trial
Northwestern EM Blog
FEBRUARY 14, 2022
The primary outcome of the study was the response in MAP three hours after the start of angiotensin II infusion. It showed improvement in blood pressure which is a clinically important parameter but not a patient-oriented outcome. However, one limitation of the study was that it was underpowered to demonstrate a mortality difference.
52 
Let's personalize your content